NEW YORK, Oct. 10, 2018 /PRNewswire/ -- EW Healthcare Partners ("EW"), a leading healthcare growth equity firm with a global investment practice, has announced the addition of two senior executives to their investment team:
- Olivier Bohuon, former CEO of Smith & Nephew, a leading global medical device company, has joined as Senior Advisor in the London office; and
- Mike Warmuth, former senior executive of Abbott Laboratories, a broad-based healthcare company with leadership positions in diagnostics, medical devices, nutrition and branded generic pharmaceuticals, has joined as Operating Partner in the New York office.
Dr. Petri Vainio, who heads the EW London office, commented: "We are extremely fortunate that both of these distinguished and accomplished executives have chosen to join our firm. Their level of expertise, US and global network of relationships, and keen interest in supporting the fastest growing companies in the pharmaceutical and medical device industries will further expand our growth potential, deepen our domain expertise, and be of great value to the management teams of our portfolio companies."
Olivier Bohuon is Appointed Senior Advisor in the London Office
Olivier Bohuon has extensive international healthcare leadership experience with a number of the most successful pharmaceutical and medical device companies in Europe and the United States. He brings deep knowledge of pharmaceuticals and healthcare in today's global environment as well as executive and board leadership in the medical technology industry.
Olivier retired recently as CEO of Smith & Nephew, a leading global medical device company headquartered in London and part of the FTSE 100 Index. During his tenure at SNN, Olivier led the restructuring of the company, significantly strengthening the company's foundations. SNN underwent important and necessary changes, and SNN's share price nearly doubled under his stewardship. Olivier is well-known to EW Healthcare Partners as a result of our portfolio company, Bioventus, which was spun out of SNN, with SNN retaining a 49% stake.
Before joining SNN, Olivier was the CEO of the Pierre Fabre Group, a private multinational pharmaceutical company headquartered in France.
Prior to Pierre Fabre, he had a successful career spanning ten years with Abbott Laboratories as Executive Vice-President of the Abbott Corporation and President of its pharmaceutical division. During his long career with Abbott, Olivier also served as the group's President for European operations as well as President of Abbott International.
Previously, Olivier held commercial leadership positions at GlaxoSmithKline as Senior Vice President and Director for European Commercial Operations.
Today Olivier is a senior independent director at Shire plc, one of the leading global specialty pharmaceutical companies with a $40B market cap where he is also a member of the Science and Technology Committee. He serves as Vice Chairman of LEO Pharma's Board of Directors, and is a Board member of Smiths Group plc and a supervisory Board member of Virbac Group SA. Olivier is also a Member of the French National Academy of Pharmacy and a Member of the French Technology Academy.
Originally from Paris, France Olivier received his Doctorate in Pharmacy in 1983 from the University of Paris XI, and his Master's degree in Business Administration from École des Hautes Études Commerciales (HEC) in Paris. Olivier was awarded Knight of the Legion d'Honneur, the highest French order of merit for military and civil merits, an order originally established in 1802 by Napoléon Bonaparte.
Mike Warmuth is Appointed Operating Partner in the New York Office
Mike Warmuth has spent his entire previous career with Abbott Laboratories, having joined the manufacturing development program immediately after university.
Most recently, he spent five years as Executive Vice President, leading the Established Pharmaceuticals division, which is a leader in the sale of branded generics in emerging markets. The Established Pharmaceuticals division of Abbott is in the top ten largest generics companies globally, with revenues of >$4 billion. Mike held full P&L responsibility for this division, which covers several therapeutic areas including gastroenterology, women's health, cardiovascular and metabolic disorders, pain and CNS and respiratory drugs and vaccines. During his tenure, he led multiple M&A transactions at Abbott, including the acquisition of Chile-based CFR Pharmaceuticals for $2.9 billion in May 2014, followed by Russian pharmaceutical company, Veropharm, for $631 million in June 2014.
Prior to Established Pharmaceuticals, he spent almost three years as the Senior Vice President of Diagnostics, running Abbott's global core laboratory diagnostics business. Prior thereto, Mike spent a brief period as GM of the Hematology division within the Diagnostics business unit. Before this, he was Vice President of the Global Engineering Services business. From 2004 to 2006, he was Division VP, Operations for the Quality and Global Pharmaceutical Operations team.
Mike received his Bachelor's degree in Business Administration from the University of Wisconsin-Whitewater and his Master's degree in Business Administration from Northwestern University.
About EW Healthcare Partners
With over $3.0 billion under management, EW Healthcare Partners is one of the largest and oldest growth equity firms pursuing investments in pharmaceuticals, medical devices, healthcare services, and healthcare information technology. Since its founding in 1985, EW Healthcare Partners has maintained its singular commitment to the healthcare industry and has been involved in the founding, investing and/or management of over 150 healthcare companies, ranging across sectors, stages and geographies. The team is comprised of over 20 senior investment professionals with offices in Palo Alto, Houston, New York, and London. For more information, see www.ewhealthcare.com.
SOURCE EW Healthcare Partners